Topical pimecrolimus versus betamethasone for oral lichen planus: a randomized clinical trial
Ezzatt, Ola; Helmy, Iman M;
Abstract
Oral lichen plans (OLP) is a potentially malignant inflammatory mucocutaneous disease. CD133 is an investigated surface marker for cancer stem-like cells (CSCs) that may be involved in tumor initiation in head and neck carcinomas. We compared short-term clinical effectiveness of topical pimecrolimus as selective inflammatory cytokine release inhibitor with betamethasone cream for erosive/atrophic OLP and investigated the influence of this therapy on CD133 expression.
Other data
| Title | Topical pimecrolimus versus betamethasone for oral lichen planus: a randomized clinical trial | Authors | Ezzatt, Ola ; Helmy, Iman M | Keywords | Betamethasone; CD133; Cancer stem cells; Oral lichen planus; Pimecrolimus | Issue Date | Feb-2019 | Publisher | SPRINGER HEIDELBERG | Journal | Clinical oral investigations | ISSN | 1432-6981 1436-3771 |
DOI | 10.1007/s00784-018-2519-6 | PubMed ID | 29909565 | Scopus ID | 2-s2.0-85048543954 | Web of science ID | WOS:000456712300052 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.